The ADAMTS5 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 5) antibody is a critical tool for studying the role of ADAMTS5. an extracellular matrix-degrading enzyme belonging to the ADAMTS family. ADAMTS5 is primarily known for its ability to cleave aggrecan, a major proteoglycan in cartilage, contributing to cartilage breakdown in osteoarthritis (OA). Research has identified ADAMTS5 as a key mediator in pathological conditions involving extracellular matrix remodeling, including arthritis, atherosclerosis, and cancer metastasis. Its overexpression is linked to accelerated cartilage degradation, making it a therapeutic target for OA. Antibodies against ADAMTS5 are widely used in research to detect enzyme expression, localization, and activity in tissues or cell cultures. They enable investigations into ADAMTS5 regulation, substrate interactions, and inhibition mechanisms, often through techniques like Western blotting, immunohistochemistry, or functional assays. Studies using ADAMTS5-neutralizing antibodies in preclinical models have shown reduced cartilage damage, highlighting its therapeutic potential. However, challenges remain in balancing inhibition efficacy with off-target effects due to structural similarities within the ADAMTS family. Ongoing research aims to refine antibody specificity and explore clinical applications, positioning ADAMTS5 antibodies as valuable tools for both mechanistic studies and drug development in connective tissue disorders.